RKRichard Kurupi

Richard Kurupi

*This is an algorithmically generated author record based on publicly available information.

Richard Kurupi has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS-mutant neuroblastoma

    by Ronald D. Hill, Krista M. Dalton, Richard Kurupi, Yanli Xing, Jamie M. Slaughter, Jane Roberts, Victor A. Kehinde, Kun Zhang, Bin Hu, Li Wang, et al.

    Neuroblastoma (NB) is the most common extracranial solid tumor in children. Patients with relapsed or refractory (R/R) high-risk (HR) NB exhibit poor outcomes despite intensive multimodal therapy. Although MAPK pathway activation is prominent in HRNB, FDA-approved MEK inhibitors and KRAS G12C inhibitors have shown limited preclinical single-agent activity in HRNB. Daraxonrasib (RMC-6236), a potent and selective RAS(ON) inhibitor, has demonstrated activity in preclinical models and early-phase clinical trials of RAS-mutant adult cancers. A subset of R/R HRNB tumors harbors diverse RAS mutations, providing a rationale for investigating RMC-6236 in this setting. Here, we evaluated the therapeutic efficacy and effects of oncogenic signaling modulation of RMC-6236 across NB models with RAS pathway activation. As a single agent, RMC-6236 significantly reduced cell viability, suppressed downstream MAPK signaling, increased expression of the MAPK pathway effector BIM, and induced cell death in RAS-mutant NB models as well as in NF1-mutant NB models. In vivo, RMC-6236 demonstrated on-target activity, significantly inhibited tumor growth, and extended survival in RAS-mutant HRNB mouse models. Furthermore, RMC-6236 induced BIM upregulation and promoted BIM:BCL-2 complexes in RAS-mutant NB. As such, the BCL-2 inhibitor venetoclax further potentiated RMC-6236-mediated killing by disrupting these complexes. Together, these findings identify RMC-6236 as a promising targeted therapy for RAS-mutant NB and support its clinical investigation, both as a single agent and in combination with venetoclax, in this patient population.

  • Open Access

    Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities

    by Ashenafi Bulle, Yali Chen, Huaping Li, Timothy Hung-Po Chen, Iftikhar Ali Khawar, Lin Li, Yu Wang, Peng Liu, Vikas Kumar Somani, Richard Kurupi, et al.

    Acquired resistance limits the therapeutic efficacy of KRAS-MAPK inhibitors in pancreatic ductal adenocarcinoma (PDAC). As transcriptional plasticity and epithelial-to-mesenchymal transition (EMT) have been implicated in resistance, we sought to study the molecular mechanisms driving these changes to uncover actionable vulnerabilities. Sustained KRAS-MAPK inhibition induced interferon (IFN) and NF-κB signaling and promoted cell state change mimicking an EMT state associated with drug resistance. Network analysis identified the IFN-inducible E3 ubiquitin ligase TRIM22 as a central regulator of this response. Mechanistically, TRIM22 promoted proteasomal degradation of IκBα, resulting in sustained NF-κB and EMT program activation that coincided with a basal-like transcriptional cell state. TRIM22 expression was driven by IRF1 and IRF9 following relief of ERK-mediated transcriptional repression during pathway inhibition. EMT induction was accompanied by marked upregulation of TROP2 (TACSTD2), an NF-κB target gene enriched in basal-like PDAC cell states. Combining TROP2-directed antibody–drug conjugate sacituzumab govitecan with KRAS or ERK inhibitors significantly suppressed PDAC tumor growth in xenograft models. Overall, prolonged KRAS-MAPK inhibition activates an IFN–TRIM22–NF-κB axis that drives EMT and therapeutic resistance in PDAC, while revealing TROP2 as a clinically actionable vulnerability to overcome acquired resistance. Significance: TRIM22 drives interferon-induced EMT and NF-κB–dependent TROP2 upregulation to drive resistance to KRAS-MAPK inhibition in pancreatic cancer, which can be overcome by combining sacituzumab govitecan with KRAS-MAPK inhibitors.


  • Epithelial-mesenchymal transition and resistance to EGFR inhibitors

    by Sheeba Jacob, Richard Kurupi, Anthony C. Faber

  • Open Access

    Abstract 362: MYCN-amplified neuroblastoma is addicted to iron and vulnerable to ferroptosis

    by Konstantinos V. Floros, Mia O. Johnson-Berro, Richard Kurupi, Carter K. Fairchild, Krista Dalton, Bin Hu, Madhavi Puchalapalli, Mikhail G. Dozmorov, Jennifer E. Koblinski, James A. Olzmann, et al.

    MYCN is amplified in 20% to 25% of neuroblastoma, and MYCN-amplified neuroblastoma contributes to a large percent of pediatric cancer-related deaths. Therapy improvements for this subtype of cancer are a high priority. Ferroptosis is an iron-dependent, oxidative form of cell death that is counteracted mainly by the production of Glutathione Peroxidase 4 (GPX4), a phospholipid hydroperoxidase that is produced through the glutathione pathway. The identification of cancers that may benefit from ferroptosis inducers are just emerging. Here we uncover a MYCN-dependent therapeutic vulnerability in neuroblastoma. Namely, amplified MYCN rewires the cell through expression of key receptors, ultimately enhancing iron influx through increased expression of the iron import transferrin receptor 1 (TFR1). Accumulating iron causes reactive oxygen species (ROS) production, and MYCN-amplified neuroblastomas show enhanced reliance on the system Xc- cystine/glutamate antiporter for ROS detoxification through increased transcription of this receptor. By performing metabolomics, we demonstrate that the transsulfuration pathway is also activated by MYCN. The increased activation of both pathways leads to cysteine accumulation that results in inhibition of lipid peroxidation. Utilizing drugs that target the main components of the glutathione and transsulfuration pathway we sensitize the MYCN neuroblastomas to ferroptotic cell death. These data provide novel insights into how MYCN alters the transcriptome in neuroblastoma to confer growth and survival advantages and simultaneously sheds light on the mechanism of action of ferroptosis inducers with potential application in other types of cancer. Citation Format: Konstantinos V. Floros, Mia O. Johnson-Berro, Richard Kurupi, Carter K. Fairchild, Krista Dalton, Bin Hu, Madhavi Puchalapalli, Mikhail G. Dozmorov, Jennifer E. Koblinski, James A. Olzmann, Lauren A. Cowart, Anthony C. Faber. MYCN-amplified neuroblastoma is addicted to iron and vulnerable to ferroptosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 362.